High Court Won't Mull Double Avandia Damages For Insurers

Law360, New York (April 15, 2013, 1:24 PM EDT) -- The U.S. Supreme Court refused Monday to review a decision allowing Humana Inc. to seek double damages from GlaxoSmithKline PLC in a putative class action over costs for Medicare patients allegedly harmed by diabetes drug Avandia, despite GSK’s argument that the remedy shouldn't be available to private insurers.

In a brief order, the high court denied without comment GSK’s petition for writ of certiorari, filed after a Third Circuit decision that revived a suit by Humana Medical Plan Inc. and Humana Insurance Co. against the drugmaker....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.